Results 71 to 80 of about 9,396,775 (321)

Peptide‐based ligand antagonists block a Vibrio cholerae adhesin

FEBS Letters, EarlyView.
The structure of a peptide‐binding domain of the Vibrio cholerae adhesin FrhA was solved by X‐ray crystallography, revealing how the inhibitory peptide AGYTD binds tightly at its Ca2+‐coordinated pocket. Structure‐guided design incorporating D‐amino acids enhanced binding affinity, providing a foundation for developing anti‐adhesion therapeutics ...
Mingyu Wang, Grace Du, Charity Yongo‐Luwawa, Angelina Lu, Brett Kinrade, Kim Munro, Karl E. Klose, William D. Lubell, Peter Davies, Shuaiqi Guo   +9 more
wiley   +1 more source

Pride and Prejudice during the COVID-19 Pandemic: The Misfortune of Inappropriate Clinical Trial Design

Journal of Epidemiology and Global Health, 2020
Coronavirus Disease 2019 (COVID-19) is a rapidly evolving global pandemic for which more than a thousand clinical trials have been registered to secure therapeutic effectiveness, expeditiously.
Shahrukh K. Hashmi, Edward De Vol, Fazal Hussain   +2 more
doaj   +1 more source

Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and ε-aminocaproic acid - a meta-analysis of randomised and observational trials of over 30.000 patients [PDF]

, 2013
Background: To compare the effect of aprotinin with the effect of lysine analogues (tranexamic acid and ε-aminocaproic acid) on early mortality in three subgroups of patients: low, intermediate and high risk of cardiac surgery.
Herrmann, Eva, Meybohm, Patrick, Nierhoff, Julia, Zacharowski, Kai   +3 more
core   +3 more sources

Comparing self‐reported race and genetic ancestry for identifying potential differentially methylated sites in endometrial cancer: insights from African ancestry proportions using machine learning models

Molecular Oncology, EarlyView.
Integrating ancestry, differential methylation analysis, and machine learning, we identified robust epigenetic signature genes (ESGs) and Core‐ESGs in Black and White women with endometrial cancer. Core‐ESGs (namely APOBEC1 and PLEKHG5) methylation levels were significantly associated with survival, with tumors from high African ancestry (THA) showing ...
Huma Asif, J. Julie Kim
wiley   +1 more source

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
The design of clinical trials in Alzheimer's disease (AD) must consider the development of new plasma, cerebrospinal fluid (CSF), and imaging biomarkers.
Ronald C. Petersen, Ana Graf, Chris Brady, Susan De Santi, Hana Florian, Jaren Landen, Mike Pontecorvo, Christopher Randolph, Kaycee Sink, Maria Carrillo, Christopher J. Weber   +10 more
doaj   +1 more source

A modified Sequential Organ Failure Assessment score for dengue: development, evaluation and proposal for use in clinical trials

BMC Infectious Diseases, 2022
Background Dengue is a neglected tropical disease, for which no therapeutic agents have shown clinical efficacy to date. Clinical trials have used strikingly variable clinical endpoints, which hampers reproducibility and comparability of findings.
Angela McBride, Nguyen Lam Vuong, Nguyen Van Hao, Nguyen Quang Huy, Ho Quang Chanh, Nguyen Thi Xuan Chau, Nguyen Minh Nguyet, Damien K. Ming, Nguyen Thanh Ngoc, Phung Tran Huy Nhat, Nguyen Thanh Phong, Luong Thi Hue Tai, Phan Vinh Tho, Dinh The Trung, Dong Thi Hoai Tam, Huynh Trung Trieu, Ronald Bertus Geskus, Martin J. Llewelyn, C. Louise Thwaites, Sophie Yacoub   +19 more
doaj   +1 more source

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension [PDF]

, 2018
Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or ...
Achiron, Anat, Airas, Laura, Al Khedr, Abdullatif, Alvarez Cermeño, Jose Carlos, Arnold, Douglas L, Ayuso, Guillermo Izquierdo, Bandari, Daniel, Bartholomé, Emmanuel, Baum, Karl, Bergamaschi, Roberto, Berger, Joseph, Berthele, Achim, Bhan, Virender, Blevins, Gregg, Boyko, Alexey, Brassat, David, Brochet, Bruno, Brunet, Donald, Cadavid, Diego, Camac, Ann, Campbell, Nolan, Camu, William, Chang, Ih, Chefranova, Zanna, Cohan, Stanley, Comi, Giancarlo, Conway, Jill, Cottone, Salvatore, Czarnecki, Maciej, D'Hooghe, Marie, Debouverie, Marc, Devonshire, Virginia, Deykin, Aaron, Drozdowski, Wieslaw, Duddy, Martin, Dufek, Michal, Duquette, Pierre, Edwards, Keith, Elovaara, Irina, Eralinna, Juha-Pekka, Escartin, Antonio, Evdoshenko, Evgeny, Fabian, Michelle, Faiss, Juergen, Fernandez, Oscar Fernandez, Flachenecker, Peter, Florin, Jack, Forrestal, Fiona, Frederiksen, Jette, Freedman, Mark, Freedman, Mark S, Freedman, Steven, Frequin, Stephan, Fryze, Waldemar, Gairin, Xavier Montalban, Garcia-Merino, Antonio, Garwacki, Dennis, Goldman, Myla, Goldman, Myla D, Gran, Bruno, Grand'Maison, François, Grimaldi, Luigi, Gunnarsson, Martin, Hardiman, Orla, Harrison, Daniel, Harrower, Timothy, Hartung, Hans-Peter, Havrdová, Eva Kubala, Havrdová, Eva Kubala, Hernandez Perez, Miguel Angel, Herrman, Craig, Hertmanowska, Hanka, Ho, Pei-Ran, Hobart, Jeremy, Hohlfeld, Reinhard, Huang, Deren, Hupperts, Raymond, Ilkowski, Jan, Jacques, François, Javed, Adil, Jeffery, Douglas, Jeffery, Douglas, Kamin, Stephen, Kaminska, Anna, Kanovsky, Petr, Kant, Matthias, Kapoor, Raju, Kapoor, Raju, Karussis, Dimitrios, Katsamakis, George, Khabirov, Farit, Khatri, Bhupendra, Killestein, Joep, Klodowska-Duda, Gabriela, Krumbholz, Markus, Lallana, José Meca, Langer-Gould, Annette, Lapierre, Yves, Laplaud, David, Lassek, Christoph, Lebrun Frenay, Christine, Lee, Liesly, Lee, Martin, Lucas, Nisha, Lycke, Jan, Lynch, Sharon, Maciejowski, Maciej, Maeurer, Mathias, Mancardi, Giovanni Luigi, Martin, Claes, Massacesi, Luca, Mattison, Paul, Mattson, David, Mcguigan, Christopher, Meuth, Sven, Mikol, Dan, Miller, Aaron, Miller, Tamara, Miravalle, Augusto, Morra, Vincenzo Brescia, Morrow, Sarah, Moses, Harold, Motta, Ewa, Muley, Suraj, Napier, James, Nicholas, Richard, Nielsen, Allen, Nocentini, Ugo, Oreja-Guevara, Celia, Pachner, Andrew, Pandolfo, Massimo, Pardo, Gabriel, Pearson, Owen, Pelletier, Jean, Petersen, Thor, Picone, Maryann, Piehl, Fredrik, Podemski, Ryszard, Potemkowski, Andrzej, Rashid, Waqar, Ravnborg, Mads, Robertson, Derrick, Rog, David, Rog, Teresa, Roshanisefat, Homayoun, Royal, Walter, Saiz Hinarejos, Albert, Salvetti, Marco, Sarasoja, Taneli, Scarpini, Elio, Schrijver, Hans, Sellebjerg, Finn, Sellebjerg, Finn, Selmaj, Krzysztof, Sharrack, Basil, Sheppard, Christopher, Silber, Eli, Sivertseva, Stella, Sola, Patrizia, Steiner, Deborah, Stelmasiak, Zbigniew, Stepien, Adam, Stetkarova, Ivana, Sundstrom, Peter, Talabova, Marika, Tedeschi, Gioacchino, Thrower, Ben, Trojano, Maria, Turner, Ben, Tutaj, Andrzej, Twyman, Cary, Van Dijl, Ronald, van Munster, Erik, Van Wijmeersch, Bart, Vermersch, Patrick, Vukusi, Sandra, Waubant, Emmanuelle, Wendt, Jeanette, Williams, Anna, Woolmore, John, Yadav, Vijayshree, Yakupov, Eduard, Yeung, Michael, Young, Carolyn, Yu, Bei, Zabad, Rana, Zaborski, Jacek, Zaffaroni, Mauro, Zarelli, Greg, Ziemssen, Tjalf   +189 more
core   +2 more sources

A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression‐free survival

Molecular Oncology, EarlyView.
There is an unmet need in metastatic breast cancer patients to monitor therapy response in real time. In this study, we show how a noninvasive and affordable strategy based on sequencing of plasma samples with longitudinal tracking of tumour fraction paired with a statistical model provides valuable information on treatment response in advance of the ...
Emma J. Beddowes, Mario Ortega Duran, Solon Karapanagiotis, Alistair Martin, Meiling Gao, Riccardo Masina, Ramona Woitek, James Tanner, Fleur Tippin, Justine Kane, Jonathan Lay, Anja Brouwer, Stephen‐John Sammut, Suet‐Feung Chin, Davina Gale, Dana W. Y. Tsui, Sarah‐Jane Dawson, Nitzan Rosenfeld, Maurizio Callari, Oscar M. Rueda, Carlos Caldas   +20 more
wiley   +1 more source

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

Molecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser, Florian Krumbach, Eyleen Corrales, Geoffroy Andrieux, Christian Preisinger, Franziska Liss, Alexandra Golzmann, Melanie Boerries, Kerstin Becker, Ruth Knüchel, Stefan Garczyk, Bernhard Lüscher   +11 more
wiley   +1 more source